Law360, New York (December 19, 2011, 6:48 PM EST) -- On Sept. 22, 2011, the U.S. Court of Appeals for the Sixth Circuit ruled in Smith v. Wyeth Inc. that former brand manufacturers of Reglan — a prescription drug used to treat certain gastric disorders — could not be held liable for injuries caused by their competitors’ generic versions of the drug. On Nov. 22, 2011, the court denied plaintiffs’ petition for rehearing en banc.
In doing so, the Sixth Circuit became the first appellate court to address, and reject, the argument that the U.S. Supreme Court’s recent preemption decision in Pliva v. Mensing (2011) either altered state law claims against...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!